Group 1 - The company expects to achieve an annual revenue of approximately 664 million yuan in 2025, which represents an increase of about 179 million yuan compared to the previous year, reflecting a year-on-year growth of approximately 36.82% [1] - The net profit attributable to the parent company's owners is expected to be around -154 million yuan, which is a decrease of approximately 52.57 million yuan compared to the same period last year [1]

证券代码：688079 证券简称：美迪凯 公告编号：2026-003 二、本次交易进展情况 截至本公告披露日，公司、光学半导体公司以及富浙绍芯等相关方已就本次交 易正式签署了《浙江美迪凯光学半导体有限公司之增资协议》《浙江美迪凯光学半 导体有限公司之股东协议》《浙江美迪凯光学半导体有限公司之增资协议和股东协 议之保证协议》，协议条款与此前基本保持一致。并且，光学半导体公司已收到富 浙绍芯缴付的全部现金增资款项共计人民币2亿元。 本次增资完成后，光学半导体公司注册资本由人民币 1,008,888,889 元增加至 人民币 1,101,447,503 元。公司持有光学半导体公司的股权比例将变更为 82.44%， 仍为其控股股东，不会导致公司合并报表范围发生变更，届时其股权结构如下表所 示，最终以工商变更登记结果为准。 | 序号 | | 股东名称 | 认缴注册资本 （人民币/元） | 持股比例 | | --- | --- | --- | --- | --- | | 1 | 美迪凯 | | 908,000,000 | 82.44% | | 2 | 服务贸易创新发展引导基金 （有限合伙） | | 100,888,889 ...

证券代码：688079 证券简称：美迪凯 公告编号：2026-004 杭州美迪凯光电科技股份有限公司 2025 年年度业绩预亏公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、本期业绩预告情况 （一）业绩预告期间 2025 年 1 月 1 日至 2025 年 12 月 31 日。 （二）业绩预告情况 （1）经杭州美迪凯光电科技股份有限公司（以下简称"公司"）财务部门 初步测算，预计 2025 年年度实现营业收入 66,425.70 万元左右，与上年同期相 比，将增加 17,874.58 万元左右，同比增加 36.82%左右。 （2）预计 2025 年年度实现归属于母公司所有者的净利润-15,441.40 万元 左右，与上年同期相比，减少 5,256.82 万元左右。 （3）预计归属于母公司所有者的扣除非经常性损益后净利润-15,694.67 万 元左右，与上年同期相比，减少 6,385.95 万元左右。 归属于母公司所有者的净利润：-10,184.58 万元。归属于母公司所有者的 扣除非经常性损益的净利润：-9,3 ...

格隆汇1月20日｜有投资者在互动平台向美迪凯提问：请问贵司关于"光刻用掩模版衬底的认证"的进 展？美迪凯回复称，关于光刻用掩模版衬底，公司已完成了其整套生产工艺的开发，并已开始逐步向客 户送样，我们将持续推动相关工作的进行。 ...

证券日报网讯 1月19日，美迪凯在互动平台回答投资者提问时表示，公司始终认为，真正的科技含量与 市场好感，源于对核心技术的长期深耕与迭代。公司与优秀客户的深度合作，正是基于此坚实的技术信 任。市场调研与客户协同从未停止，公司相信，将战略定力与市场嗅觉相结合，在核心技术主航道上进 行创新拓展，定能行稳致远。 （文章来源：证券日报） ...

Group 1 - The company, Medike, stated that it has not produced Faraday rotator products as of the current date [1]

证券日报网讯1月19日，美迪凯在互动平台回答投资者提问时表示，公司始终围绕主营业务领域，即半 导体声光学、半导体微纳电路、精密光学、微纳光学及智慧终端的研发、制造和销售进行发展。在相关 精密制造工艺中，公司开发了光刻用掩模版衬底并已开始送样，这是光刻工序中的关键耗材。同时，公 司为生产需要引进了先进的光刻设备(如用于新产品开发的12英寸90nm节点KrF光刻机)。公司将持续深 耕专业领域，以精密制造技术服务于半导体及光学产业。 ...

Core Viewpoint - The company, MediKey, is progressing as planned with its project to manufacture 2 billion semiconductor devices, with overall construction completed and currently in the final stages of acceptance [1] Group 1: Project Development - The construction of the semiconductor device manufacturing project is on schedule and has been completed [1] - The project is now in the final stages of acceptance [1] Group 2: Technology and Market Opportunities - The company is closely monitoring advancements in cutting-edge technologies [1] - MediKey is leveraging its technology platforms in semiconductor optics and MEMS micro-nano manufacturing to evaluate market opportunities cautiously [1]

Core Viewpoint - The company is focusing on building a versatile technology platform based on its strong foundation in semiconductor optics, MEMS micro-manufacturing, and advanced packaging, while closely monitoring the transformative changes brought by the AI industry, including trends in cutting-edge technologies like CPO (Co-Packaged Optics) [1] Group 1 - The company's current strategic core is centered on semiconductor optics, MEMS micro-manufacturing, and advanced packaging [1] - The company is committed to developing a future-oriented general technology platform [1] - The company will carefully evaluate any significant capacity planning and strategic shifts based on its technology platform, market demand, and customer collaboration [1]

Group 1 - The core point of the article is that Meidike clarified that as of now, the Faraday optical plate is not part of the company's business segments or main products [1]